12 Jun 2019

VICI VENOUS STENT: FDA OKs VICI Venous Stent to treat Iliofemoral obstructive disease

    The U.S Food and Drug Administration has approved Boston Scientific’s VICI Venous Stent System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked by a blood clot or compressed by anatomical anomalies.

0
28 Mar 2019

FDA evaluating stents, balloons with paclitaxel coating following JAHA evaluation

A December study in The Journal of the American Heart Association by Konstantinos Katsanos, MD, of Rion, Greece, et al, reported a higher risk of death after balloons and stents used to open vessels in the legs were coated with an anti-inflammatory chemo agent called paclitaxel. “Further investigations are urgently

0
02 Jan 2019

BOSTON SCIENTIFIC ACQUIRES REST OF MILLIPEDE IN $4.8 BILLION YEAR-LONG SHOPPING SPREE

After a year of holding the option to acquire Millipede, Boston Scientific decided to do it a year before the option ran out. When the pair signed the agreement last January, Boston Scientific paid $90 million for a portion of the mitral regurgitation startup’s shares. Now, Boston Scientific is spending $325 million

0
31 Dec 2018

BOSTON SCIENTIFIC LINES UP FINANCING FOR ITS $4B BTG ACQUISITION

Now that everyone has said yes, Boston Scientific has gone to the banks to sign a number of new lending agreements, including a large credit facility it could use to finance its $4.2 billion acquisition offer for British medical device maker BTG plc. The information, which came from recently posted

0
30 Dec 2018

BOSTON SCIENTIFIC ACQUIRING BTG

Boston Scientific has reached an agreement on the terms of a recommended offer to acquire BTG plc., a United Kingdom-based company that develops and commercializes products used in minimally-invasive procedures, targeting vascular diseases and cancer, as well as acute care pharmaceuticals. Under the terms of the transaction, holders of BTG’s

0
21 Nov 2018

BOSTON SCIENTIFIC ACQUIRING BTG

    Boston Scientific has reached an agreement on the terms of a recommended offer to acquire BTG plc., a United Kingdom-based company that develops and commercializes products used in minimally-invasive procedures, targeting vascular diseases and cancer, as well as acute care pharmaceuticals. Under the terms of the transaction, holders

0